Urbilat

Urbilat Brand names, Urbilat Analogs

Urbilat Brand Names Mixture

No information avaliable

Urbilat Chemical_Formula

C₂₀H₂₃NS

Urbilat RX_link

No information avaliable

Urbilat fda sheet

Urbilat msds (material safety sheet)

Urbilat Synthesis Reference

No information avaliable

Urbilat Molecular Weight

309.469 g/mol

Urbilat Melting Point

< 25 ^oC

Urbilat H₂O Solubility

Soluble as HCl salt

Urbilat State

Liquid

Urbilat LogP

5.7

Urbilat Dosage Forms

Tablets (oral, 1 mg)

Urbilat Indication

Used for the symptomatic treatment of parkinsonism.

Urbilat Pharmacology

Metixene is a tertiary antimuscarinic with actions similar to those of atropine; it also has antihistaminic and direct antispasmodic properties. It is used for the symptomatic treatment of parkinsonism, including the alleviation of the extrapyramidal syndrome induced by other drugs such as phenothiazines, but, like other antimuscarinics, it is of no value against tardive dyskinesias. Metixene has been discontinued.

Urbilat Absorption

Absorbed in the gastrointestinal tract following oral administration, however the extent of absorption is not known.

Urbilat side effects and Toxicity

Signs of overdose include dilated and sluggish pupils, warm, dry skin, facial flushing, decreased secretions of the mouth, pharynx, nose, and bronchi, foul-smelling breath, elevated temperature, tachycardia, cardiac arrhythmias, decreased bowel sounds, urinary retention, delirium, disorientation, anxiety, hallucinations, illusions, confusion, incoherence, agitation, hyperactivity, ataxia, loss of memory, paranoia, combativeness, and seizures.

Urbilat Patient Information

Urbilat Organisms Affected

Humans and other mammals